IL-23IL-23

Back to Disease

February 2026

Medication Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?

March 2026

Protecting Joints: Inhibiting Structural Damage in PsA With Guselkumab

February 2026

Medication Review: Anti-Drug Antibody Development With Guselkumab in Psoriasis, PsA & IBD

February 2026

FAQ: Screening Tools APPs Use to Identify PsA, SpA, or IBD and Refer Early

January 2026

Journal Club: Guselkumab Binds To CD64+ IL-23–Producing Myeloid Cells to Neutralize IL-23 Signals

February 2026

Medication Review: Laboratory Monitoring Recommendations for Guselkumab in PSO, PsA, and IBD

February 2026

Medication Review: Safety and Efficacy of Guselkumab in the Treatment of CD and UC

January 2026

FAQ: What Is the Correlation of CD64 and IL-23 Expression in Inflamed Joint, Skin, and Gut Tissue?

December 2025

FAQ: What is the Normal Role of CD64 in Innate and Adaptive Immunity?

December 2025

Medication Review: Describe the Dual Mechanism of Action of Guselkumab

sectionimg

dotsimg

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play